Pharma & Life Sciences

Oral Testosterone Ester Composition for Treating Liver Diseases

The European Patent Office granted Patent EP3824296A1 to Lipocine Inc. covering an oral pharmaceutical composition comprising testosterone tridecanoate and/or testosterone dodecanoate for treating liver diseases. The patent designates 33 European Patent Convention states including Germany, France, the United Kingdom, Italy, and Spain. Inventors include Patel, Chidambaram, Nachaegari, Byrne, Kim, and Baker.

Opioid Overdose Prevention Formulations - Indivior Inc.

The European Patent Office published patent application EP3793558A1 for Indivior Inc., covering formulations and methods for preventing opioid overdose using intranasal drug delivery. The patent application designates 35 European states including major markets. This patent grants Indivior exclusive rights to its opioid overdose prevention technology in European markets.

Anthocyanin Preparations for Cardiovascular Disease Prevention

The European Patent Office published EP3784251A1, a patent application by MedPalett AS covering preparations containing anthocyanins for use in preventing and treating cardiovascular diseases. The application claims compositions under IPC classifications A61K 31/7048 and A61P 9/00 with inventors including Rosario Lizio, Sara Liebaña Viñas, Aldelhak Zoubir, Michael Muma, and Tim Schaeck. The patent designates all EU member states and related countries.

HSK44459 Phase III IPF trial by Haisco

HSK44459 Phase III IPF trial by Haisco

Phase II Trial XKH001 Injection for COPD

ClinicalTrials.gov registered a new Phase II clinical trial (NCT07519499) evaluating XKH001 injection for the treatment of chronic obstructive pulmonary disease (COPD). The trial is listed in the clinical trial registry database maintained by the National Library of Medicine.

Tacrolimus vs Crisaborole Atopic Dermatitis 8-Week Trial

ClinicalTrials.gov registered a new randomized controlled trial comparing tacrolimus ointment versus crisaborole ointment for treating atopic dermatitis in participants 12 years and older over an 8-week period. The single-center study being conducted in the United States is estimated to enroll 80 participants and is currently recruiting.

Chest X-rays Detect Congenital Heart Disease in Newborns

The National Library of Medicine registered clinical trial NCT07520149 on ClinicalTrials.gov, investigating the use of chest X-rays as a diagnostic tool to detect congenital heart disease in newborn infants. The observational study is designed to evaluate the effectiveness and accuracy of radiographic imaging in identifying cardiac abnormalities in the neonatal population.

YN001 Phase 2b Trial for Coronary Atherosclerosis

ClinicalTrials.gov registered a new Phase 2b clinical trial (NCT07521007) for YN001, an investigational product being evaluated for treatment of coronary atherosclerosis. The trial is sponsored by YN and will enroll patients to assess efficacy and safety endpoints.

Peribulbar Block Study, Lidocaine Additives, Sohag University

The National Library of Medicine registered clinical trial NCT07519694 on ClinicalTrials.gov, a randomized study evaluating lidocaine additives for peribulbar anesthesia in ophthalmic procedures conducted at Sohag University, Egypt. The trial examines whether specific additives enhance the effectiveness of lidocaine in peribulbar nerve blocks during eye surgery.

ClinicalTrials.gov

ClinicalTrials.gov